Levofloxacin for the prevention of febrile episodes in non-Hodgkin lymphoma patients treated with CHOP plus rituximab in a randomized controlled trial.

Furthermore, levofloxacin prophylaxis maintained chemotherapy intensity and showed a trend toward reducing chemotherapy dose reduction, hospitalization, septic shock and infection-related mortality.

also in 53,322 other papers

Secondary endpoints included febrile neutropenia-free survival, defined as the time from randomization to the first episode of febrile neutropenia (fever accompanied by an absolute neutrophil count [ANC] < 500/μL or < 1000/μL with a decreasing trend) 19 , the rate of febrile neutropenia, septic shock, infection-related mortality, all-cause mortality, chemotherapy dose reduction rate and relative dose intensity.

also in 47,180 other papers